386MO Trastuzumab duocarmazine versus physician's choice therapy in pre-treated HER2-positive metastatic breast cancer: Final results of the phase III TULIP trial

According to research from the phase 3 TULIP trial—presented during the 2023 ESMO Congress—treatment with the HER2-targeting antibody-drug conjugate trastuzumab duocarmazine (T-Duo) confirmed a trend toward a numerically prolonged OS among patients with pretreated metastatic HER2-positive breast cancer, compared with patients treated with physician’s choice (PC; trastuzumab combined with capecitabine or vinorelbine or eribulin or lapatinib plus capecitabine). Median OS was 21.0 months and 19.5 months T-Duo and PC groups, respectively (HR 0.87 [95% CI: 0.68, 1.12]; P=0.236).